DMD and Duchenne muscular dystrophy: Notably, the efficiencies of the SpCas9 system when reframing the ΔEx51 mutation and restoring dystrophin expression are comparable to that of the AsCas12a system in human DMD ΔEx51 myoblasts and a patient-derived xenograft DMD mouse model [155].